olopatadine hydrochloride profile

Olopatadine Hydrochloride: An antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5282402
CHEBI ID	31933
SCHEMBL ID	23213
MeSH ID	M0325753

Synonym
kw-4679
alo-4943a
patanase
olopatadine hydrochloride
pataday
o-ppds
allelock
dibenz(b,e)oxepin-2-acetic acid, 11-(3-dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (z)-
kw 4679
11-((z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride
dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (z)-
11-((z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride
alo4943a
MLS001401465
olopatadine hcl
smr000469220
allelock (tn)
140462-76-6
D01192
olopatadine hydrochloride (jp17/usp)
patanol (tn)
O0361 ,
kw4679
olopatadine (as hydrochloride)
A807652
(z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid hydrochloride
dtxsid0046486 ,
tox21_112242
dtxcid8026486
cas-140462-76-6
CCG-101141
olopatadine hydrochloride [usan:usp]
alo 4943a
olopine
unii-2xg66w44kf
patadine
2xg66w44kf ,
de 114
olopax
pazeo
BCP9001022
olopatadine hydrochloride [who-dd]
ryaltris component olopatadine hydrochloride
olopatadine hydrochloride [jan]
olopatadine hydrochloride [usan]
olopatadine hydrochloride [mi]
olopatadine hydrochloride [usp monograph]
olopatadine hydrochloride [orange book]
olopatadine hydrochloride [usp-rs]
olopatadine hydrochloride component of ryaltris
olopatadine hydrochloride [mart.]
olopatadine hydrochloride [ema epar]
olopatadine hydrochloride [vandf]
AKOS015895232
S2494
olopatadine (hydrochloride)
HY-B0426A
NC00391
SCHEMBL23213
tox21_112242_1
NCGC00263532-01
KS-1228
HVRLZEKDTUEKQH-NOILCQHBSA-N
Q-201511
AKOS025149118
(z)-11-[3-(dimethylamino)propylidene]-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid hydrochloride
mfcd00875716
hydrochloride, olopatadine
EX-A1347
olopatadine hydrochlorde
SR-01000763388-4
olopatadine hydrochloride, united states pharmacopeia (usp) reference standard
C72607
olopatadine hydrochloride, >=98% (hplc)
CHEBI:31933
alo4943a;kw4679
olopatadine hydrochloride (opatanol)
dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, hydrochloride (1:1), (11z)-
Q27255766
(z)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)aceticacidhydrochloride
olopatadine hydrochloride- bio-x
BO164171
2-[(2z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid hydrochloride
EN300-25953569
al4943a
2-{2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl}acetic acid hydrochloride
EN300-19652056
Z2568665949
1010110-90-3
cvs eye allergy itch relief
once daily relief
olopatadine hydrochloride ophthalmic solutiontwice daily
olopatadine hydrochloride ophthalmic
olopatadine hydrochloride ophthalmic solutiononce daily relief
pataday twice a day relief
olopatadine hydrochloride nasal
(11-((1z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenzo(b,e)oxepin-2-yl)acetic acid monohydrochloride
olopatadine hydrochloride ophthalmic solution
cvs eye allergy itch relieftwice daily
eye allergy itch and redness relief
eye allergy itch and redness relieftwice daily relief
pataday once daily relief
olopatadine hydrochloride (usp monograph)
clear eyes once daily eye allergy itch relief
pataday twice daily relief
cvs eye allergy itch reliefonce daily
olopatadine hydrochloride (mart.)
olopatadine hydrochloride (usp-rs)
olopatadine hydrochloride ophthalmic solutiononce daily
olopatadine hydrochloride usp, 0.1%
eye allergy itch reliefonce daily relief
olopatadine hydrochloride (usan:usp)
eye allergy itch relief

Excerpt	Reference	Relevance
"Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available as oral, intranasal and ocular preparations. "	( Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Dimov, V; Eidelman, F; Gonzalez-Estrada, A; Reddy, K, 2017)	3.34
"Olopatadine hydrochloride (olopatadine) is an antiallergic agent with histamine H(1) receptor antagonistic action."	( Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. Kimoto, N; Tamura, T, 2009)	1.34
"Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available in three forms, including oral, intranasal and ocular preparations. "	( Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Dimov, V; Nickels, AS; Wolf, R, 2011)	1.81
"Olopatadine hydrochloride is an H1-receptor-blocker but has other anti-allergic pharmacological potencies. "	( Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells. Ito, T; Kobayashi, M; Matsubara, A; Takahashi, H; Takigawa, M; Tokura, Y, 2003)	1.76
"Olopatadine hydrochloride (olopatadine) is an anti-allergic drug that functions as a histamine H(1) antagonist and inhibits both mast cell degranulation and the release of arachidonic acid metabolites in various types of cells. "	( Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells. Hasegawa, K; Karasawa, A; Masaki, S; Matsubara, M; Ohmori, K, 2004)	1.77
"Olopatadine hydrochloride (Olopatadine) is an antiallergic drug with selective histamine H(1) receptor antagonist activity."	( Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. Furukawa, H; Kaneko, F; Nakamura, K; Takahashi, M, 2004)	1.33
"Olopatadine hydrochloride 0.1% is an effective agent for relieving the signs and symptoms of vernal keratoconjunctivitis. "	( Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density. Bilgin, LK; Corum, I; Ilhan, R; Yeniad, B, 2005)	2.13
"Olopatadine hydrochloride (olopatadine) is an antiallergic drug with histamine H(1) receptor antagonistic activity. "	( Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Hasegawa, K; Kaneko, S; Kishimoto, K; Ohmori, K; Tamura, T, 2006)	1.78
"Olopatadine hydrochloride (olopatadine) is an antiallergic agent with histamine H(1) receptor antagonistic action. "	( Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Amano, T; Chida, M; Matsubara, M; Tamura, T, 2008)	1.79
"Olopatadine hydrochloride (olopatadine) is an anti-allergic agent with histamine H1 receptor antagonistic action."	( Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats. Komai, M; Tamura, T, 2008)	1.47

Excerpt	Reference	Relevance
" Olopatadine nasal spray administered twice daily was safe and well tolerated in adolescents and adults."	( Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Amar, NJ; Brubaker, MJ; Drake, M; Hampel, FC; Marple, BF; Mohar, D; Ratner, PH; Roland, PS; Silver, LH; Turner, D; van Bavel, JH; Wall, GM, 2005)	0.64
" Olopatadine nasal spray administered twice daily was safe and well tolerated in adolescents and adults."	( Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Barnes, JR; Berger, WE; Bernstein, DI; Brubaker, MJ; Dimas, C; Finn, AF; Hampel, FC; Larsen, LV; Marple, BF; Meltzer, EO; Potts, SL; Ratner, PH; Roland, PS; Silver, LH; Wall, GM, 2005)	0.64
" Safety parameters assessed included adverse events, visual acuity, ocular signs (slit-lamp assessments), dilated fundus examinations, intraocular pressure (IOP), pulse, and blood pressure."	( Safety and tolerability of olopatadine 0.2% in children and adolescents. Edwards, MR; Gross, RD; Lichtenstein, SJ; Pasquine, TA; Robertson, SM; Wells, DT, 2007)	0.34
" All adverse events reported were mild or moderate."	( Safety and tolerability of olopatadine 0.2% in children and adolescents. Edwards, MR; Gross, RD; Lichtenstein, SJ; Pasquine, TA; Robertson, SM; Wells, DT, 2007)	0.34
"2% administered once-daily for 6 weeks is safe and well tolerated in children and adolescent patients."	( Safety and tolerability of olopatadine 0.2% in children and adolescents. Edwards, MR; Gross, RD; Lichtenstein, SJ; Pasquine, TA; Robertson, SM; Wells, DT, 2007)	0.34
" Adverse events were nonserious and infrequent in all treatment groups."	( Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Drake, M; Fairchild, CJ; Meltzer, EO; Roland, PS; Wall, GM; Wells, D, )	0.13
"When antiallergic agents are used to treat allergic conjunctivitis other than olopatadine, a particularly toxic effect on conjunctival cells associated with azelastine and ketotifen, rather than olopatadine, should be considered clinically."	( Comparison of the conjunctival toxicity of topical ocular antiallergic agents. Kim, N; Lee, JE; Lee, JS; Oum, BS, 2008)	0.35
" In both studies, subjects were evaluated based on physical/nasal examinations and adverse events (AEs)."	( Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis. Berger, WE; Casale, TB; Meltzer, EO; Ratner, PH; Wall, GM, )	0.44
" Adverse events occurred in 33."	( Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. Kaneko, K; Magara, H; Okubo, K; Okuda, M, 2010)	1.8
"Olopatadine hydrochloride 5 mg twice daily is an effective and safe treatment for perennial allergic rhinitis in children."	( Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. Kaneko, K; Magara, H; Okubo, K; Okuda, M, 2010)	3.25
" There were no serious adverse events."	( [A 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in Japan]. Ando, M; Ohno, S, 2012)	0.38
" Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety."	( Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. Bagchi, C; Chaudhuri, A; Das, NK; Hazra, A; Islam, CN; Sil, A; Tripathi, SK, 2013)	0.39
" Adverse event profiles were comparable with sedation being the commonest complaint."	( Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. Bagchi, C; Chaudhuri, A; Das, NK; Hazra, A; Islam, CN; Sil, A; Tripathi, SK, 2013)	0.39
"Olopatadine is a safe and more effective alternative to levocetirizine in the treatment of CU."	( Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. Bagchi, C; Chaudhuri, A; Das, NK; Hazra, A; Islam, CN; Sil, A; Tripathi, SK, 2013)	0.39
" Additional assessments included average morning and evening 12-hour instantaneous TNSS (iTNSS), ocular symptoms, individual symptoms, onset of action, quality of life, and adverse events (AEs)."	( Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Amar, NJ; Berman, G; Caracta, CF; Gross, GN; Tantry, SK, 2019)	0.51
" Average morning and evening 12-hour instantaneous TNSS (iTNSS), ocular symptoms, individual symptoms, onset of action, quality of life, and adverse events (AEs) were also assessed."	( Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Andrews, CP; Mohar, D; Salhi, Y; Tantry, SK, 2020)	0.56
"All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis."	( Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. Ayyappanavar, S; Gangasagara, SB; Jayanthi, CR; Kumar, K; Mittal, P; Preethi, B; Rathod, BLS; Sridhar, S, 2021)	0.86
" Average morning and evening 12-h reflective total nasal symptom score (rTNSS), instantaneous total nasal symptom score (iTNSS), reflective total ocular symptom score (rTOSS), instantaneous total ocular symptom score(iTOSS), Physician-assessed nasal symptom score (PNSS), rhinoconjunctivitis quality of life (RQLQ), rhinitis control assessment test (RCAT) and adverse events (AEs) were measured."	( Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. Chen, R; Sima, G; Zhang, Y; Zheng, D, 2022)	0.72
"GSP301 is a safe and well-tolerated medication."	( Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis. Chen, R; Sima, G; Zhang, Y; Zheng, D, 2022)	0.72
" Additional assessments included instantaneous Total Nasal Symptom Score, Pediatric Rhinoconjunctivitis Quality of Life Questionnaire, reflective Total Ocular Symptoms Score, instantaneous Total Ocular Symptoms Score, individual symptoms, Physician-assessed Nasal Symptom Score, and adverse events."	( Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis. Amar, NJ; Caracta, CF; Hampel, FC; Prenner, BM; Wu, W, 2022)	0.72
" Treatment-emergent adverse events occurred in 12."	( Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis. Amar, NJ; Caracta, CF; Hampel, FC; Prenner, BM; Wu, W, 2022)	0.72

Excerpt	Reference	Relevance
" In the multiple-dose trial, all pharmacokinetic parameters examined, except the maximum concentration, showed no difference between the first and the last administration."	( Pharmacokinetics of KW-4679 in the elderly: single-dose and multiple-dose trials. Kobayashi, H; Kobayashi, S; Nakamura, T; Shigeyama, C; Tateishi, T, 1998)	0.3
"The pharmacokinetic parameters for olopatadine in 12 healthy Chinese subjects (six males and six females) were assessed by determining olopatadine concentrations with a validated liquid chromatography-tandem mass spectrometry method."	( Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Chen, WL; Chu, NN; Li, XN; Xu, HR, 2009)	0.35
"The pharmacokinetic parameters (mean +/- SD) for olopatadine following a single dose were: maximum plasma concentration (C(max)) 69."	( Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Chen, WL; Chu, NN; Li, XN; Xu, HR, 2009)	0.35
" To assess the relative bioavailability of olopatadine in the fixed-dose nasal spray versus two monotherapies, pharmacokinetic (PK) estimates, maximum plasma concentration (Cmax), area under the plasma concentration time curve (AUC) from time 0 to the last time point with measurable concentration (AUC0-t), and AUC from time 0 to time infinity (AUC0-∞) were compared by analysis of variance."	( Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
" To evaluate the relative bioavailability of mometasone, pharmacokinetic (PK) estimates, the maximum plasma concentration (Cmax), the area under the plasma concentration time curve (AUC) from time 0 to the last time point with measurable concentration (AUC0-t), and AUC from time 0 to time infinity (AUC0-∞) were compared by analysis of variance."	( Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
" A slightly higher Cmax was observed with GSP301 than with MF, but AUC was comparable."	( Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
" Blood samples were collected at predetermined time points for pharmacokinetic analyses of the drug in plasma."	( Pharmacokinetics and pharmacodynamics of olopatadine following administration via nasogastric tube to healthy horses. Fukuda, K; Kasashima, Y; Kuroda, T; Kusano, K; Mita, H; Mizobe, F; Nagata, SI; Takizawa, Y; Tamura, N, 2019)	0.51

Excerpt	Reference	Relevance
"To determine whether Patanol in combination with the systemic antihistamine Claritin (loratadine, Schering, Kenilworth, NJ) reduces the ocular itching associated with allergic conjunctivitis more effectively than Claritin alone."	( The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Abelson, MB; Lanier, RQ, 1999)	0.3

Excerpt	Reference	Relevance
"To assess the relative bioavailability of olopatadine administered as GSP301 versus two olopatadine monotherapy nasal spray formulations."	( Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
" To assess the relative bioavailability of olopatadine in the fixed-dose nasal spray versus two monotherapies, pharmacokinetic (PK) estimates, maximum plasma concentration (Cmax), area under the plasma concentration time curve (AUC) from time 0 to the last time point with measurable concentration (AUC0-t), and AUC from time 0 to time infinity (AUC0-∞) were compared by analysis of variance."	( Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
"Olopatadine bioavailability with GSP301 was comparable with OLO-sponsor and OLO."	( Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
"To assess the relative bioavailability of mometasone administered as GSP301 FDC versus two mometasone monotherapy NS formulations."	( Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
" To evaluate the relative bioavailability of mometasone, pharmacokinetic (PK) estimates, the maximum plasma concentration (Cmax), the area under the plasma concentration time curve (AUC) from time 0 to the last time point with measurable concentration (AUC0-t), and AUC from time 0 to time infinity (AUC0-∞) were compared by analysis of variance."	( Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
"Mometasone bioavailability with GSP301 was comparable with MF-sponsor and MF monotherapies."	( Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Patel, P; Salapatek, AM; Talluri, RS; Tantry, SK, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Subject/objective symptoms improved significantly after administering the agent, and the total dosage of the combined topical steroids was also significantly decreased after administration (p<0."	( [Examination of effectiveness of olopatadine hydrochloride in atopic dermatitis]. Mashiko, M; Shimizu, H; Shimizu, T, 2005)	0.61
" Newer topical medications are being used that have multiple actions, such as an antihistaminic effect coupled with mast-cell stabilisation, and which require reduced daily dosing due to their longer duration of action."	( Pharmacotherapy of allergic eye disease. Flynn, TH; Larkin, F; Manzouri, B; Ono, SJ; Wyse, R, 2006)	0.33
"2% to vehicle (identical formation without the active ingredient) for dosing on a once-daily schedule."	( Safety and tolerability of olopatadine 0.2% in children and adolescents. Edwards, MR; Gross, RD; Lichtenstein, SJ; Pasquine, TA; Robertson, SM; Wells, DT, 2007)	0.34
" Allergy symptoms (sneezing, runny, itchy, and stuffy nose) were rated by patients at 16 time points during 12 hours after dosing and patient satisfaction was assessed at 4 and 12 hours postdose."	( Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Brubaker, M; Conroy, JP; Crenshaw, K; Garadi, R; Kaji, Y; Patel, D; Wall, GM; Whitling, A, )	0.36
" The effects of various histamine H(1) receptor antagonists on the dose-response curve for histamine were evaluated."	( The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism. Funahashi, J; Hayashi, K; Matsumoto, Y; Mori, K; Yano, H, 2008)	0.56
" The added convenience of a once-a-day dosing regimen is a major advancement in this drug class."	( Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Abelson, MB; Gomes, PJ, 2008)	0.35
"2% ophthalmic solution, fluticasone furoate nasal spray, a tear substitute, or saline nasal spray), dosed with study medication, and challenged 15 minutes later, after which ocular allergic signs and symptoms were assessed."	( A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Abelson, MB; Gomes, PJ; Kennedy, K; Mahr, T; Rosenwasser, LJ, )	0.13
" A randomized, multicenter, double-blind, parallel-group clinical study was carried out to evaluate the dose-response relationship and superiority of olopatadine hydrochloride over placebo in children aged 7 to 16 years with perennial allergic rhinitis."	( Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. Kaneko, K; Magara, H; Okubo, K; Okuda, M, 2010)	2
"This paper describes two simple, specific, accurate, and precise methods for estimation of olopatadine hydrochloride (OLO) in tablet dosage form."	( Stability-indicating high-performance column liquid chromatography and high-performance thin-layer chromatography methods for the determination of olopatadine hydrochloride in tablet dosage form. Kumar, AM; Ravi, TK; Varghese, SJ, )	0.55
" Significant improvements in iTNSS with twice-daily GSP301 occurred by 10 minutes after dosing (-1."	( Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Patel, P; Salapatek, AM; Tantry, SK, 2019)	0.51
" Multiple standard addition method was applied to enable the determination of OLO which is considered as the weakly absorbing species as well as the minor component in a challenging dosage form ratio (4:1)."	( UV spectrophotometric methods for simultaneous determination of ketorolac tromethamine and olopatadine hydrochloride: Application of multiple standard addition for assay of ophthalmic solution. El-Malla, SF; Hammad, SF; Rady, MM, 2023)	1.13

Class	Description
dibenzooxazepine	An organic heterotricyclic compound consisting of two benzene rings fused to a seven-membered ring containing one oxygen and one nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.2660	0.0007	14.5928	83.7951	AID1259369
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	2.6832	0.0002	14.3764	60.0339	AID720691
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	18.8322	0.0237	23.2282	63.5986	AID743222
geminin	Homo sapiens (human)	Potency	1.7783	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID180554	The compound was tested in vivo for inhibitory effect on 48-h homologous passive cutaneous anaphylaxis (PCA) in rats administered perorally	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID86745	Binding affinity for histamine H1 receptor from guinea pig cerebellum, using [3H]pyrilamine as radioligand at 0.1 uM	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID77121	The compound was tested in vivo for the inhibition of IgG1-mediated bronchoconstriction in guinea pig at 0.03 mg/kg administered perorally	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID141584	Binding affinity for Muscarinic acetylcholine receptor M1 from rat striatum, using [3H]quinuclidinyl benzilate as radioligand at 10 uM.	1992	Journal of medicinal chemistry, May-29, Volume: 35, Issue:11	Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	31 (11.03)	18.2507
2000's	127 (45.20)	29.6817
2010's	92 (32.74)	24.3611
2020's	31 (11.03)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	103 (32.49%)	5.53%
Reviews	27 (8.52%)	6.00%
Case Studies	18 (5.68%)	4.05%
Observational	1 (0.32%)	0.25%
Other	168 (53.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (58)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Masked, Placebo-Controlled, Proof of Concept Study to Evaluate the Short-term Safety and Efficacy of the QLT Proprietary Olopatadine Punctal Plug Delivery System in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Envir [NCT01287338]	Phase 2	143 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Lack of definitive clinical results.)
[NCT01344083]	Phase 2	60 participants (Anticipated)	Interventional	2011-04-30	Completed
A Randomized, Double-Masked, Crossover Study to Evaluate the Safety and Comfort of AL-4943A Ophthalmic Solution, 0.7% [NCT01326858]	Phase 1	50 participants (Actual)	Interventional	2011-04-30	Completed
A Single-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group, Comparative Environmental Exposure Chamber (EEC) Study to Evaluate Efficacy, Safety and Tolerability of Two Fixed Dose Combination (FDC) Products of Olopatadine Hydrochloride and Mom [NCT03444506]	Phase 2	180 participants (Actual)	Interventional	2014-01-27	Completed
A Pilot Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo Nasal Spray in Reducing Nasal Allergic Symptoms Following Ragweed Exposure in the Allergen BioCube (ABC) [NCT01076439]	Phase 4	0 participants (Actual)	Interventional		Withdrawn
[NCT01109485]	Phase 4	42 participants (Actual)	Interventional	2010-03-31	Completed
[NCT01258309]	Phase 3	129 participants (Actual)	Interventional	2010-12-31	Completed
[NCT01294969]	Phase 4	47 participants (Actual)	Interventional	2010-09-30	Completed
A Prospective, Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen [NCT00836485]	Phase 2	122 participants (Actual)	Interventional	2009-02-28	Completed
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis [NCT01037179]	Phase 3	110 participants (Actual)	Interventional	2010-02-28	Completed
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Pla [NCT06126952]	Phase 2	84 participants (Anticipated)	Interventional	2023-10-30	Recruiting
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis Wit [NCT00562159]	Phase 3	439 participants (Actual)	Interventional	2007-11-30	Completed
A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis [NCT00655109]	Phase 4	60 participants (Actual)	Interventional	2008-02-29	Completed
Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis [NCT00789555]	Phase 4	1,260 participants (Actual)	Interventional	2008-11-30	Completed
Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution Alone and In Combination on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen. [NCT01007253]	Phase 4	21 participants (Actual)	Interventional	2009-11-30	Completed
[NCT01159769]	Phase 4	215 participants (Actual)	Interventional	2010-06-30	Completed
A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis [NCT05265910]	Phase 4	58 participants (Actual)	Interventional	2021-12-14	Completed
Mast-Cell Stabilizing Effects of Olopatadine [NCT00389025]	Phase 4	24 participants (Actual)	Interventional	2006-10-31	Completed
Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis [NCT03186755]	Phase 4	42 participants (Anticipated)	Interventional	2017-06-11	Recruiting
A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivi [NCT01119287]	Phase 4	180 participants (Actual)	Interventional	2010-03-31	Completed
Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride [NCT00489398]	Phase 4	25 participants (Anticipated)	Interventional	2007-07-31	Withdrawn(stopped due to Protocol changes)
A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model [NCT01479374]	Phase 3	397 participants (Actual)	Interventional	2012-01-31	Completed
[NCT00818805]	Phase 4	50 participants (Actual)	Interventional	2008-07-31	Completed
[NCT01495338]	Phase 1	60 participants (Actual)	Interventional	2011-12-31	Completed
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients [NCT00578929]	Phase 3	2,388 participants (Actual)	Interventional	2007-09-30	Completed
A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in [NCT02631551]	Phase 3	1,180 participants (Actual)	Interventional	2016-03-31	Completed
A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis [NCT01272089]	Phase 4	300 participants (Actual)	Interventional	2011-05-31	Completed
[NCT00845195]	Phase 4	150 participants (Actual)	Interventional	2009-03-31	Completed
DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis [NCT04708821]	Phase 4	31 participants (Actual)	Interventional	2021-04-30	Completed
Phase 3 Clinical Trial to Evaluate the Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis [NCT01657240]	Phase 3	0 participants (Actual)	Interventional	2014-11-30	Withdrawn(stopped due to Formula Reformulation)
[NCT01470118]	Phase 4	127 participants (Actual)	Interventional	2011-10-31	Completed
Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen [NCT02251613]	Phase 4	50 participants (Actual)	Interventional	2013-12-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With a History of Grass Pollen Induced Rhinoconjunctivi [NCT00550550]	Phase 3	345 participants (Actual)	Interventional	2007-11-30	Completed
A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects [NCT02322216]	Phase 3	383 participants (Actual)	Interventional	2014-12-31	Completed
[NCT00979615]	Phase 4	129 participants (Actual)	Interventional	2009-09-30	Completed
A Phase III Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the CAC Model of Acute Allergic Conjunctivitis in Japanese Subjects [NCT00987272]	Phase 3	267 participants (Actual)	Interventional	2009-10-31	Completed
A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monoth [NCT02318303]	Phase 2	1,111 participants (Actual)	Interventional	2014-12-31	Completed
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% [NCT01697969]	Phase 4	17 participants (Actual)	Interventional	2012-09-30	Completed
A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC) [NCT01435460]	Phase 3	300 participants (Actual)	Interventional	2010-08-31	Completed
Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID [NCT01450176]		30 participants (Actual)	Interventional	2011-09-30	Completed
A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) [NCT01282138]	Phase 4	13 participants (Actual)	Interventional	2010-12-31	Completed
A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis [NCT00331500]	Phase 3	287 participants (Actual)	Interventional	2006-04-18	Completed
A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis [NCT05314621]	Phase 4	61 participants (Actual)	Interventional	2021-12-31	Completed
PHASE IV, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, CONTROLLED,60 DAYS, PARALLEL GROUPS, SUPERIORITY STUDY, TO COMPARE THE EFFECTIVENESS AND TOXICITY OF BEPOTASTINE 1.5% PF vs. OLOPATADINE 0.2% WITH BAK IN TREATMENT OF ALLERGIC CONJUNCTIVITIS [NCT04776096]	Phase 4	97 participants (Actual)	Interventional	2021-03-10	Completed
[NCT02161146]	Phase 3	240 participants (Actual)	Interventional	2014-06-04	Completed
Safety Study of Olopatadine Nasal Spray [NCT00578331]	Phase 3	890 participants (Actual)	Interventional	2006-12-31	Completed
A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial [NCT00691665]	Phase 4	130 participants (Actual)	Interventional	2008-05-31	Completed
Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model [NCT01743027]	Phase 3	902 participants (Actual)	Interventional	2013-01-31	Completed
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis W [NCT01700192]	Phase 3	1,482 participants (Actual)	Interventional	2013-01-31	Completed
A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model [NCT00534794]	Phase 4	79 participants (Actual)	Interventional	2007-10-31	Completed
Expression of Inflammatory Mediators in Allergic Conjunctivitis [NCT00609128]		21 participants (Actual)	Interventional	2000-09-30	Completed
[NCT00794144]	Phase 2	132 participants (Actual)	Interventional	2008-10-31	Completed
[NCT00772304]	Phase 4	102 participants (Actual)	Interventional	2008-10-31	Completed
Effect of Olopatadine Hydrochloride 0.2% Ophthalmic Solution on Epicutaneous Skin Prick Testing With Histamine and Saline [NCT00775658]		24 participants (Actual)	Interventional	2008-01-31	Completed
[NCT01732757]	Phase 4	157 participants (Actual)	Interventional	2012-11-30	Completed
A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without [NCT02478398]	Phase 3	1,025 participants (Actual)	Interventional	2015-07-20	Completed
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily [NCT01698814]	Phase 3	518 participants (Actual)	Interventional	2012-10-31	Completed
Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study - [NCT01363700]	Phase 3	87 participants (Actual)	Interventional		Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00534794 (2) [back to overview]	Change in Ocular Itch Score From Baseline
NCT00534794 (2) [back to overview]	Ocular Comfort Score at 12 Hours
NCT00550550 (4) [back to overview]	Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) Total Score Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Symptom Scores (DSS) Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)
NCT00562159 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Symptom Score (DSS) Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire With Standardized Activities (RQLQ(S)) Total Score Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)
NCT00578331 (2) [back to overview]	Average Number of Days of Rescue Medication Taken
NCT00578331 (2) [back to overview]	Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire
NCT00578929 (2) [back to overview]	Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)
NCT00578929 (2) [back to overview]	Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)
NCT00609128 (1) [back to overview]	Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine Treatment) Promotes Eosinophil Adhesion
NCT00691665 (4) [back to overview]	Mean Percent Change in Instantaneous Total Nasal Symptom Score (iTNSS) From Baseline
NCT00691665 (4) [back to overview]	Mean Percent Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline
NCT00691665 (4) [back to overview]	Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline
NCT00691665 (4) [back to overview]	Mean Percent Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline
NCT00772304 (1) [back to overview]	Product Preference Questionnaire for Immediate Taste
NCT00775658 (2) [back to overview]	The Difference in Area (cm2) of the Flare Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo.
NCT00775658 (2) [back to overview]	The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo.
NCT00789555 (6) [back to overview]	Percentage of Subjects With Change From Baseline (Day 0) in Pulse Rate Beats Per Minute (BPM) to Exit (Month 12 or Sooner)
NCT00789555 (6) [back to overview]	Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)
NCT00789555 (6) [back to overview]	Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Physical Examination Parameters to Exit (Month 12 or Sooner)
NCT00789555 (6) [back to overview]	Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Systolic) to Exit (Month 12 or Sooner)
NCT00789555 (6) [back to overview]	Self-Rated Relief Assessment at Day 30
NCT00789555 (6) [back to overview]	Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Diastolic) to Exit (Month 12 or Sooner)
NCT00794144 (1) [back to overview]	Number of Participants With Anatomic Nasal Exam Abnormalities
NCT00818805 (1) [back to overview]	"Change in Ocular Itching Score (5-point Scale) in Subjective Symptom Questionnaire"
NCT00845195 (4) [back to overview]	Mean Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline
NCT00845195 (4) [back to overview]	Mean Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline
NCT00845195 (4) [back to overview]	Mean Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline
NCT00845195 (4) [back to overview]	Mean Change in Instantaneous Total Nasal Symptom Scores (iTNSS) From Baseline
NCT00979615 (5) [back to overview]	Mean Change Postnasal Drip Reflective Score
NCT00979615 (5) [back to overview]	Mean Change Nasal Congestion Reflective Score
NCT00979615 (5) [back to overview]	Mean Change in Sneezing Reflective Score
NCT00979615 (5) [back to overview]	Mean Change in Rhinorrhea Reflective Score
NCT00979615 (5) [back to overview]	Mean Change in 2-week rTNSS From Baseline
NCT01007253 (6) [back to overview]	Total Number of Eosinophils
NCT01007253 (6) [back to overview]	Total Number of Sneezes
NCT01007253 (6) [back to overview]	Total Nasal Symptoms Score Difference
NCT01007253 (6) [back to overview]	Total Eye Symptoms Score Difference
NCT01007253 (6) [back to overview]	Change in Tryptase Level (Across Nasal Challenges)
NCT01007253 (6) [back to overview]	Change in Histamine Level (Across Nasal Challenges)
NCT01119287 (2) [back to overview]	Mean Change From Baseline in Staff-Assessed Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)], Maxidex and Placebo
NCT01119287 (2) [back to overview]	Mean Change From Baseline Patient-Assessed Ocular Itching, Area Under the Curve From Time Zero to Hour 3 [AUC (0-3)], Patanol and Placebo
NCT01159769 (2) [back to overview]	Overall Patient Satisfaction
NCT01159769 (2) [back to overview]	Overall Patient Satisfaction
NCT01282138 (2) [back to overview]	Change From Baseline in Patient-Assessed Ocular Itching, Environmental Exposure Chamber (EEC), at 3 Hours
NCT01282138 (2) [back to overview]	Change From Baseline in Patient-Assessed Ocular Itching, Conjunctival Allergen Provocation Test (CAPT), at 3 Hours
NCT01363700 (4) [back to overview]	Mean Hyperemia Score Compared to Olopatadine Period2
NCT01363700 (4) [back to overview]	Mean Hyperemia Score Compared to Placebo Period1
NCT01363700 (4) [back to overview]	Mean Ocular Itching Score Compared to Olopatadine Period2
NCT01363700 (4) [back to overview]	Mean Ocular Itching Score Compared to Placebo Period1
NCT01435460 (4) [back to overview]	Bulbar Conjunctival Injection
NCT01435460 (4) [back to overview]	Ocular Itching
NCT01435460 (4) [back to overview]	Ocular Itching
NCT01435460 (4) [back to overview]	Bulbar Conjunctival Injection
NCT01470118 (8) [back to overview]	Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
NCT01470118 (8) [back to overview]	Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
NCT01470118 (8) [back to overview]	Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
NCT01470118 (8) [back to overview]	Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
NCT01470118 (8) [back to overview]	Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
NCT01470118 (8) [back to overview]	Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24
NCT01470118 (8) [back to overview]	Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16
NCT01470118 (8) [back to overview]	Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
NCT01479374 (7) [back to overview]	Mean Conjunctival Redness at 24 Hours Duration of Action
NCT01479374 (7) [back to overview]	Mean Conjunctival Redness at Onset of Action
NCT01479374 (7) [back to overview]	Mean Ocular Itching at 16 Hours Duration of Action
NCT01479374 (7) [back to overview]	Mean Ocular Itching at 24 Hours Duration of Action
NCT01479374 (7) [back to overview]	Mean Ocular Itching at Onset of Action
NCT01479374 (7) [back to overview]	Mean Total Redness at 24 Hours Duration of Action
NCT01479374 (7) [back to overview]	Mean Conjunctival Redness at 16 Hours Duration of Action
NCT01697969 (1) [back to overview]	Patient-Assessed Ocular Itching
NCT01698814 (1) [back to overview]	Adverse Events
NCT01700192 (7) [back to overview]	Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment
NCT01700192 (7) [back to overview]	Average Total Combined Rhinoconjunctivitis Score (TCS) During Last 8 Weeks of Treatment
NCT01700192 (7) [back to overview]	Number of Participants Who Discontinue Study Drug Due to an AE
NCT01700192 (7) [back to overview]	Number of Participants Who Experience At Least One Adverse Event (AE)
NCT01700192 (7) [back to overview]	Average Rhinitis Daily Medication Score (Rhinitis DMS) During Last 8 Weeks of Treatment
NCT01700192 (7) [back to overview]	Average Allergic Rhinitis/Rhinoconjunctivitis Symptoms Assessed by Visual Analogue Scale (VAS) During Last 8 Weeks of Treatment
NCT01700192 (7) [back to overview]	Average Rhinitis Daily Symptom Score (Rhinitis DSS) During Last 8 Weeks of Treatment
NCT01732757 (11) [back to overview]	Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Ocular Itching Evaluated by the Subject at 5 and 7 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Percentage of Subject Eyes in Each Category of the Itching Score Distribution Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Percentage of Subjects With a Zero Itch Score at 3, 5, and 7 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Percentage of Subjects With Minimal Itching Score at 3, 5, and 7 Minutes Post Challenge on Day 0
NCT01732757 (11) [back to overview]	Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 0
NCT01743027 (8) [back to overview]	Mean Conjunctival Redness at 24 Hours Duration of Action
NCT01743027 (8) [back to overview]	Mean Conjunctival Redness at Onset of Action
NCT01743027 (8) [back to overview]	Mean Ocular Itching at 24 Hours Duration of Action
NCT01743027 (8) [back to overview]	Proportion of Ocular Itching Responders at Onset of Action
NCT01743027 (8) [back to overview]	Mean Ocular Itching at Onset of Action
NCT01743027 (8) [back to overview]	Mean Total Redness at 24 Hours Duration of Action
NCT01743027 (8) [back to overview]	Mean Total Redness at Onset of Action
NCT01743027 (8) [back to overview]	Proportion of Itch Responders at 24 Hours Duration of Action
NCT02161146 (2) [back to overview]	Ocular Itching Score
NCT02161146 (2) [back to overview]	Conjunctival Hyperemia Score
NCT02251613 (2) [back to overview]	Mean Ocular Itching at 7 Minutes Post-CAC, Day 1
NCT02251613 (2) [back to overview]	Mean Conjunctival Hyperemia at 20 Minutes Post-CAC, Day 1
NCT02318303 (1) [back to overview]	Change in rTNSS From Baseline to End of Treatment
NCT02322216 (1) [back to overview]	Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14
NCT02478398 (7) [back to overview]	Average Rhinoconjunctivitis (RC) DMS During the Peak RS
NCT02478398 (7) [back to overview]	Average Rhinoconjunctivitis (RC) DSS During the Peak RS
NCT02478398 (7) [back to overview]	Average TCS During the Entire RS
NCT02478398 (7) [back to overview]	Percentage of Participants Reporting Anaphylaxis and/or Systemic Allergic Reactions
NCT02478398 (7) [back to overview]	Percentage of Participants Treated With Epinephrine
NCT02478398 (7) [back to overview]	Total Combined Score (TCS) During the Peak Ragweed Season (RS)
NCT02478398 (7) [back to overview]	Percentage of Participants Reporting Pre-specified Local Application Site Reactions
NCT02631551 (1) [back to overview]	Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment.

Change in Ocular Itch Score From Baseline

Ocular itch was measured on a 0 (none) to 4 (severe itch with continual desire to rub eyes) scale. Negative values for change from baseline represent favorable outcomes. (NCT00534794)
Timeframe: 0 hours, 12 hours

Intervention	units on a scale (Mean)
Elestat	-1.5
Pataday	-1.5

Intervention	Percent change of TOSS from baseline (Least Squares Mean)
Olopatadine 0.6% 1 Spray	-25.02
Vehicle 1 Spray	-6.09
Olopatadine 0.6% 2 Sprays	-25.03
Vehicle 2 Sprays	-9.46

Intervention	Percent change of TNSS from baseline (Least Squares Mean)
Olopatadine 0.6% 1 Spray	-25.10
Vehicle 1 Spray	-18.17
Olopatadine 0.6% 2 Sprays	-26.35
Vehicle 2 Sprays	-21.21

Intervention	eosinophils/square cm epithelial cells (Mean)
Tears From Olopatadine Treated Eyes	4517
Tears From Untreated Eyes	5004

Intervention	Percent change (Mean)
Olopatadine HCL Nasal Spray, 0.6%	-45.26
Fluticasone Propionate Nasal Spray, 50 Mcg	-48.8

Intervention	Percent change (Mean)
Olopatadine HCL Nasal Spray, 0.6%	-36.54
Fluticasone Propionate Nasal Spray, 50 Mcg	-41.63

Intervention	Percent change (Mean)
Olopatadine HCL Nasal Spray, 0.6%	-45.37
Fluticasone Propionate Nasal Spray, 50 Mcg	-47.35

Intervention	Percent change (Mean)
Olopatadine HCL Nasal Spray, 0.6%	-38.52
Fluticasone Propionate Nasal Spray, 50 Mcg	-40.59

Intervention	Percentage of participants (Number)
	Preferred Azelastine Strongly	Preferred Azelastine Somewhat	Preferred Azelastine Slightly	Same	Preferred Olopatadine Slightly	Preferred Olopatadine Somewhat	Preferred Olopatadine Strongly
Olopatadine 0.6% / Azelastine 137 Mcg	26.47	10.78	5.88	15.69	8.82	8.82	23.53

Intervention	Percentage of subjects (Number)
	Decrease greater than 30 BPM	Decrease 21-30 BPM	Decrease 11-20 BPM	Decrease 1-10 BPM	No Change	Increase 1-10 BPM	Increase 11-20 BPM	Increase 21-30 BPM	Increase greater than 30 BPM
PATANASE	0.0	0.7	7.5	27.2	7.5	38.7	16.8	1.4	0.2
Patanase Vehicle, pH 3.7	0.0	1.2	9.2	30.4	6.5	38.9	9.9	3.6	0.2
Patanase Vehicle, pH 7.0	0.0	0.5	6.2	34.7	7.9	39.7	8.9	1.4	0.7

Intervention	Percentage of subjects (Number)
	Anatomic Abnormalities	Bleeding	Infection	Possible Ulcerations
PATANASE	0.8	0.8	0.3	0.5
Patanase Vehicle, pH 3.7	1.3	1.0	1.0	0.5
Patanase Vehicle, pH 7.0	0.3	2.6	0.0	1.6

Intervention	Percentage of subjects (Number)
	Head/EENT	Neck	Cardiovascular	Pulmonary	Abdomen	Skin and Extremities	Neurological	Lymph Nodes	Musculoskeletal
PATANASE	5.2	0.0	0.0	0.7	0.0	1.2	0.7	0.0	0.0
Patanase Vehicle, pH 3.7	4.2	0.7	0.5	0.2	0.0	0.5	0.0	0.2	0.5
Patanase Vehicle, pH 7.0	4.6	0.0	0.3	0.3	0.3	1.3	0.0	0.0	0.5

Intervention	Percentage of subjects (Number)
	Decrease greater than 30 mmHg	Decrease 21-30 mmHg	Decrease 11-20 mmHg	Decrease 1-10 mmHg	No change	Increase 1-10 mmHg	Increase 11-20 mmHg	Increase 21-30 mmHg	Increase greater than 30 mmHg
PATANASE	0.5	1.0	11.8	35.3	4.6	35.1	10.6	1.2	0.0
Patanase Vehicle, pH 3.7	1.2	2.4	9.2	36.3	5.3	33.4	10.2	1.9	0.0
Patanase Vehicle, pH 7.0	0.5	2.4	10.0	35.4	5.3	34.4	10.5	1.2	0.2

Intervention	Participants (Number)
Olopatadine Hydrochloride Nasal Spray 0.6%	3
Olopatadine Hydrochloride Nasal Spray Vehicle	2

Intervention	Units on a scale (Mean)
	15 minutes	30 minutes	45 minutes	60 minutes	75 minutes	90 minutes	105 minutes	120 minutes	135 minutes	150 minutes	165 minutes	180 minutes
Olopatadine 0.1% One Eye	0.19	0.44	0.50	0.67	0.81	0.92	0.94	1.03	1.17	1.25	1.28	1.39
Placebo (Olopatadine)	0.06	0.33	0.50	0.75	0.92	0.92	1.03	1.19	1.33	1.36	1.39	1.44
Placebo (Tranilast)	0.08	0.28	0.56	0.61	0.78	0.94	0.97	1.08	1.19	1.25	1.33	1.47
Tranilast 0.5% One Eye	0.11	0.25	0.36	0.50	0.67	0.86	0.86	1.03	1.14	1.14	1.14	1.39

Intervention	Units on a scale (Mean)
Olopatadine HCl Nasal Spray, 0.6%	2.76
Azelastine HCl Nasal Spray, 0.1%	2.54

Intervention	Units on a scale (Mean)
Olopatadine HCl Nasal Spray, 0.6%	4.28
Azelastine HCl Nasal Spray, 0.1%	4.15

Intervention	Units on a scale (Mean)
Olopatadine HCl Nasal Spray, 0.6%	4.22
Azelastine HCl Nasal Spray, 0.1%	4.04

Intervention	Units on a scale (Mean)
Olopatadine HCl Nasal Spray, 0.6%	2.64
Azelastine HCl Nasal Spray, 0.1%	2.49

Intervention	hours x units on a scale (Mean)
	Baseline (Visit 3, pre-treatment)	Visit 6 (Day 9 of treatment)	Change
Maxidex/Cat Allergic	16.823	11.313	-5.511
Maxidex/Ragweed Allergic	18.120	11.671	-6.450
Tears Naturale II/Cat Allergic	17.572	13.824	-3.748
Tears Naturale II/Ragweed Allergic	19.362	15.786	-3.576

Intervention	hours x units on a scale (Mean)
	Baseline (Visit 2, pre-treatment)	Visit 5 (Day 8 of treatment)	Change
Patanol/Cat Allergic	5.904	2.881	-3.023
Patanol/Ragweed Allergic	4.776	2.630	-2.146
Tears Naturale II/Cat Allergic	5.654	2.586	-3.068
Tears Naturale II/Ragweed Allergic	5.669	3.990	-1.680

olopatadine hydrochloride

Description

Cross-References

Synonyms (113)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Bioassays (46)

Research

Studies (281)

Market Indicators

Research Demand Index: 51.91

Study Types

Clinical Trials (58)

Trial Overview

Trial Outcomes

Change in Ocular Itch Score From Baseline

Ocular Comfort Score at 12 Hours

Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) Total Score Over the Entire GPS

Participant Average Rhinoconjunctivitis Daily Symptom Scores (DSS) Over the Entire GPS

Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS

Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)

Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS

Participant Average Rhinoconjunctivitis Daily Symptom Score (DSS) Over the Entire GPS

Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire With Standardized Activities (RQLQ(S)) Total Score Over the Entire GPS

Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)

Average Number of Days of Rescue Medication Taken

Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire

Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)

Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)

Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine Treatment) Promotes Eosinophil Adhesion

Mean Percent Change in Instantaneous Total Nasal Symptom Score (iTNSS) From Baseline

Mean Percent Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline

Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline

Mean Percent Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline

Product Preference Questionnaire for Immediate Taste

The Difference in Area (cm2) of the Flare Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo.

The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo.

Percentage of Subjects With Change From Baseline (Day 0) in Pulse Rate Beats Per Minute (BPM) to Exit (Month 12 or Sooner)

Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)

Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Physical Examination Parameters to Exit (Month 12 or Sooner)

Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Systolic) to Exit (Month 12 or Sooner)

Self-Rated Relief Assessment at Day 30

Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Diastolic) to Exit (Month 12 or Sooner)

Number of Participants With Anatomic Nasal Exam Abnormalities

"Change in Ocular Itching Score (5-point Scale) in Subjective Symptom Questionnaire"

Mean Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline

Mean Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline

Mean Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline

Mean Change in Instantaneous Total Nasal Symptom Scores (iTNSS) From Baseline

Mean Change Postnasal Drip Reflective Score

Mean Change Nasal Congestion Reflective Score

Mean Change in Sneezing Reflective Score

Mean Change in Rhinorrhea Reflective Score

Mean Change in 2-week rTNSS From Baseline

Total Number of Eosinophils

Total Number of Sneezes

Total Nasal Symptoms Score Difference

Total Eye Symptoms Score Difference

Change in Tryptase Level (Across Nasal Challenges)

Change in Histamine Level (Across Nasal Challenges)

Mean Change From Baseline in Staff-Assessed Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)], Maxidex and Placebo

Mean Change From Baseline Patient-Assessed Ocular Itching, Area Under the Curve From Time Zero to Hour 3 [AUC (0-3)], Patanol and Placebo

Overall Patient Satisfaction

Overall Patient Satisfaction

Change From Baseline in Patient-Assessed Ocular Itching, Environmental Exposure Chamber (EEC), at 3 Hours

Change From Baseline in Patient-Assessed Ocular Itching, Conjunctival Allergen Provocation Test (CAPT), at 3 Hours

Mean Hyperemia Score Compared to Olopatadine Period2

Mean Hyperemia Score Compared to Placebo Period1

Mean Ocular Itching Score Compared to Olopatadine Period2

Mean Ocular Itching Score Compared to Placebo Period1

Bulbar Conjunctival Injection

Ocular Itching

Intervention	score (Mean)
Epinastine (DE-114) Ophthalmic Solution	2.4
Olopatadine Ophthalmic Solution	2.7
Placebo Ophthalmic Solution	3.7

Intervention	Scores on a Scale (Mean)
	7 Minutes	15 Minutes	20 Minutes
LASTACAFT® (Alcaftadine 0.25%)	1.36	1.64	1.67
Pataday™ (Olopatadine 0.2%)	1.47	1.67	1.65
Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)	1.83	2.00	1.94

Intervention	Scores on a Scale (Mean)
	3 Minutes	5 Minutes	7 Minutes
LASTACAFT® (Alcaftadine 0.25%)	0.64	0.84	0.93
Pataday™ (Olopatadine 0.2%)	0.97	1.16	1.01
Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)	2.27	2.19	1.96

Intervention	Units on a scale (Mean)
	7 min post-CAC	15 min post-CAC	20 min post-CAC
AL-4943A	1.5	1.8	1.8
Pataday	1.9	2.1	2.1
Vehicle	2.1	2.3	2.3

Intervention	Units on a scale (Mean)
	3 min post-CAC	5 min post-CAC	7 min post-CAC
AL-4943A	0.7	0.8	0.8
Pataday	0.9	1.1	1.0
Vehicle	2.2	2.3	2.1

Intervention	participants (Number)
	Deaths	Non-Fatal Serious Adverse Events	Discontinuations Due to an Adverse Event
AL-4943A	0	0	0
AL-4943A Vehicle	0	0	2

Intervention	Scores on a Scale (Mean)
Lastacaft®	0.40
Pataday™	0.76
Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)	2.00

Intervention	Percentage of Subject Eyes (Number)
	0	0.5	1.0	1.5	2.0	2.5	3.0	3.5	4.0
Lastacaft®	41.7	32.1	12.5	3.5	5.8	4.2	0.3	0.0	0.0
Pataday™	34.3	24.0	20.8	7.7	6.7	5.1	1.3	0.0	0.0
Placebo (Dextran 70 0.1%/Hydroxypropyl Methylcellulose 0.3%)	8.7	10.9	8.0	6.4	17.9	22.8	15.1	5.8	4.5

Intervention	units on a scale (Least Squares Mean)
	7 minutes post-CAC	15 minutes post-CAC	20 minutes post-CAC
AL-4943A	1.92	2.04	2.08
PATADAY	2.01	2.21	2.19
PATANOL	1.97	2.10	2.07
Vehicle	2.09	2.22	2.23

Intervention	units on a scale (Least Squares Mean)
	3 minutes post-CAC	5 minutes post-CAC	7 minutes post-CAC
AL-4943A	1.01	1.22	1.25
PATADAY	1.33	1.48	1.41
PATANOL	1.53	1.70	1.64
Vehicle	2.30	2.37	2.14